US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zenas BioPharma Inc.

21.52

+1.014.90%

Volume:410.24K

Turnover:8.77M

Market Cap:906.00M

PE:-4.05

High:22.18

Open:20.59

Low:20.45

Close:20.51

52wk High:26.25

52wk Low:5.83

Shares:42.11M

Float Shares:21.07M

Volume Ratio:1.39

T/O Rate:1.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.3099

EPS(LYR):-11.8940

ROE:-88.40%

ROA:-47.94%

PB:3.78

PE(LYR):-1.81

Loading ...

Overview Company News Filings

Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization

Royalty Pharma Plc - to Receive 5.5% Royalty on Obexelimab Sales

THOMSON REUTERS

Zenas Biopharma and Royalty Pharma Enter Into Obexelimab Funding Agreement for up to $300 Million

THOMSON REUTERS

Zenas BioPharma Inc. to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Zenas BioPharma Q2 EPS $(1.25) Misses $(1.04) Estimate

Zenas BioPharma Inc. Grants Stock Options to New Employee Under Nasdaq Rule, Vesting Over Four Years

Zenas BioPharma Inc. to Present at Jefferies Global Healthcare Conference

Zenas BioPharma Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

BRIEF-Zenas Biopharma Reports First Quarter 2025 Financial Results

Zenas BioPharma Q1 EPS $(0.80) Beats $(1.05) Estimate, Sales $10.00M Beat $1.67M Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ZBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":21.515,"timestamp":1757361600000,"preClose":20.51,"halted":0,"volume":410242,"delay":0,"floatShares":21071865,"shares":42110313,"eps":-5.309901,"marketStatus":"Pre-Mkt","change":1.005,"latestTime":"09-09 06:46:40 EDT","open":20.59,"high":22.18,"low":20.4517,"amount":8769334.222726,"amplitude":0.084266,"askPrice":34.42,"askSize":200,"bidPrice":8.61,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-5.309901,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757424600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":21.515,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":21.515,"preClose":21.515,"latestTime":"18:13 EDT","volume":1217,"amount":26188.455,"timestamp":1757369631463},"volumeRatio":1.3898041407245387,"impliedVol":0.9229,"impliedVolPercentile":0.8788},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":21071865,"roa":"-47.94%","roe":"-88.40%","lyrEps":-11.893967,"volumeRatio":1.3898041407245387,"shares":42110313,"dividePrice":0,"high":22.18,"amplitude":0.084266,"preClose":20.51,"low":20.4517,"week52Low":5.83,"pbRate":"3.78","psRate":"60.40","week52High":26.2508,"institutionHeld":0,"latestPrice":21.515,"eps":-5.309901,"divideRate":0,"volume":410242,"delay":0,"ttmEps":-5.309901,"open":20.59,"prevYearClose":8.19,"prevWeekClose":20.51,"prevMonthClose":16,"prevQuarterClose":9.69,"fiveDayClose":16,"twentyDayClose":14.63,"sixtyDayClose":12.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25},{"market":"US","date":"2025-05-15","symbol":"ZBIO","fiscalQuarterEnding":"2025/03","expectedEps":-1.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.7143,"buy":0.2857,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.7143,"analysts":7,"updateTime":1742702400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2025-09-08","current":-4.879369,"percent":0.195918,"low":-19.592941,"twenty":-4.698498,"median":-2.983224,"eighty":-2.375023,"high":-1.802568,"avg":-4.97419,"sd":4.507753,"marketCap":863682519},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-08","current":-4.879369,"twenty":-4.698498,"median":-2.983224,"eighty":-2.375023,"marketCap":863682519}],"updateTime":1757414722750},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564809631","title":"Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2564809631","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564809631?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:05","pubTimestamp":1756811117,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. has entered into a funding agreement with Royalty Pharma for up to $300 million to support the development and potential U.S. commercial launch of obexelimab, a treatment for IgG4-Related Disease and other autoimmune conditions. The agreement includes an initial $75 million upfront payment, with additional funding contingent on the success of the Phase 3 INDIGO trial and U.S. FDA approvals for IgG4-RD and SLE. In return, Royalty Pharma will receive a 5.5% royalty on worldwide net sales of obexelimab. This partnership aims to accelerate the clinical and commercial advancement of obexelimab, reflecting a significant opportunity in the treatment of autoimmune diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ze","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL90KTqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","IE00B3QW5Z07.USD","BK4585","LU0314104364.USD","ZBIO","BK4139","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","LU2210150020.SGD","NDAQ","RPRX","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2564809661","title":"Royalty Pharma Plc - to Receive 5.5% Royalty on Obexelimab Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2564809661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564809661?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:05","pubTimestamp":1756811100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA38VWXX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RPRX","ZBIO","BK4139","BK4007"],"gpt_icon":0},{"id":"2564668809","title":"Zenas Biopharma and Royalty Pharma Enter Into Obexelimab Funding Agreement for up to $300 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2564668809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564668809?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:05","pubTimestamp":1756811100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA38VWXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RPRX","BK4007","ZBIO","BK4139"],"gpt_icon":0},{"id":"2562800687","title":"Zenas BioPharma Inc. to Present at Morgan Stanley 23rd Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2562800687","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562800687?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:05","pubTimestamp":1756206311,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc., a clinical-stage global biopharmaceutical company focused on autoimmune disease therapies, is set to present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 7:45 a.m. ET. Live webcasts and archived replays of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on August 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL1xYSvV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","LU1162221912.USD","IE00BZ1G4Q59.USD","LU1548497426.USD","LU2271345857.HKD","LU2133065610.SGD","LU0006306889.USD","LU1720051017.SGD","IE00BGHQF748.EUR","BK4516","BK4534","LU1244550494.USD","LU1244550577.SGD","LU1244550221.USD","IE00BKVL7J92.USD","LU0795875086.SGD","LU1668664300.SGD","LU2210150020.SGD","LU2089284900.SGD","LU0320765646.SGD","LU1732799900.SGD","ZBIO","LU1720051108.HKD","LU0158827781.USD","BK4588","LU0158827948.USD","IE00BKPKM429.USD","LU1363072403.SGD","LU0106831901.USD","LU0912757837.SGD","BK4581","BK4504","LU0971096721.USD","LU1074936037.SGD","LU2357305700.SGD","BK4139","LU2210149790.SGD","IE00B64PRP62.GBP","LU1732800096.USD","LU1989772840.SGD","IE00B3QW5Z07.USD","LU0098860793.USD","LU1989772923.USD","NDAQ","LU0234570918.USD","LU2023251221.USD","LU0225283273.USD","BK4127","BK4112"],"gpt_icon":0},{"id":"2558490836","title":"Zenas BioPharma Q2 EPS $(1.25) Misses $(1.04) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558490836","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558490836?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:14","pubTimestamp":1754997253,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(1.04) by 20.19 percent. This is a 94.84 percent increase over losses of $(24.23) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47054644/zenas-biopharma-q2-eps-1-25-misses-1-04-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2545170294","title":"Zenas BioPharma Inc. Grants Stock Options to New Employee Under Nasdaq Rule, Vesting Over Four Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170294","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170294?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:15","pubTimestamp":1750450510,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., June 20, 2025 - Zenas BioPharma Inc. , a global biopharmaceutical company focused on autoimmune disease therapies, has announced a new stock option grant for a newly hired employee. On June 16, 2025, the company's Compensation Committee approved a non-qualified stock option to purchase 112,000 shares of Zenas' common stock as an inducement material for the employee's entry into the company. The stock option, priced at $9.97 per share, the closing price on the grant date, has a ten-year term. Vesting of the stock options will occur over four years, with 25% vesting on the first anniversary of employment and the remainder vesting in 36 equal monthly installments, contingent on continued employment with Zenas. This grant aligns with Nasdaq Listing Rule 5635 and is governed by an Inducement Option Award Agreement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL9GxK0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4588","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BKPKM429.USD","BK4112","NDAQ","ZBIO","IE00B3QW5Z07.USD","BK4139","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2539254796","title":"Zenas BioPharma Inc. to Present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2539254796","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539254796?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:05","pubTimestamp":1748516709,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc., a clinical-stage global biopharmaceutical company focused on therapies for autoimmune diseases, is set to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. A live webcast and archived replay of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on May 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL1lYSH2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","LU2095319765.USD","IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","BK4588","IE00BGHQF748.EUR","ZBIO","LU2210150020.SGD"],"gpt_icon":0},{"id":"2535139501","title":"Zenas BioPharma Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2535139501","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535139501?lang=en_us&edition=fundamental","pubTime":"2025-05-16 19:17","pubTimestamp":1747394220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 07:17 ET (11:17 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2535841300","title":"BRIEF-Zenas Biopharma Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535841300","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535841300?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:37","pubTimestamp":1747309057,"startTime":"0","endTime":"0","summary":"BRIEF-Zenas Biopharma Reports First Quarter 2025 Financial Results May 15 (Reuters) - Zenas Biopharma Inc ZBIO.O:ZENAS BIOPHARMA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUA9W8LV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2535846178","title":"Zenas BioPharma Q1 EPS $(0.80) Beats $(1.05) Estimate, Sales $10.00M Beat $1.67M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535846178","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535846178?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:15","pubTimestamp":1747307730,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.05) by 23.81 percent. This is a 95.53 percent increase over losses of $(17.89) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45432726/zenas-biopharma-q1-eps-0-80-beats-1-05-estimate-sales-10-00m-beat-1-67m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}